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ORIGINAL ARTICLE
Cost-effectiveness of using a gene expression proﬁling test to
aid in identifying the primary tumour in patients with cancer of
unknown primary
MB Hannouf1, E Winquist2, SM Mahmud3, M Brackstone2,4, S Sarma1, G Rodrigues5,1, P Rogan6,2, JS Hoch7,8,9 and GS Zaric10,1
We aimed to investigate the cost-effectiveness of a 2000-gene-expression proﬁling (GEP) test to help identify the primary tumor site
when clinicopathological diagnostic evaluation was inconclusive in patients with cancer of unknown primary (CUP). We built a
decision-analytic-model to project the lifetime clinical and economic consequences of different clinical management strategies for
CUP. The model was parameterized using follow-up data from the Manitoba Cancer Registry, cost data from Manitoba Health
administrative databases and secondary sources. The 2000-GEP-based strategy compared to current clinical practice resulted in an
incremental cost-effectiveness ratio (ICER) of $44,151 per quality-adjusted life years (QALY) gained. The total annual-budget impact
was $36.2 million per year. A value-of-information analysis revealed that the expected value of perfect information about the test’s
clinical impact was $4.2 million per year. The 2000-GEP test should be considered for adoption in CUP. Field evaluations of the test
are associated with a large societal beneﬁt.
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INTRODUCTION
The Canadian Cancer Society estimates that approximately
186,400 new cases of cancer will occur in Canada in 2014.1
Approximately 4% are of metastatic cancer types not readily
classiﬁed in the course of the initial diagnostic work up.2
International and Canadian clinical guidelines recommend a
further diagnostic work-up for these metastatic patients including
immunohistochemical (IHC) analyses.2 In the past decade,
improvements in the number and accuracy of IHC stains have
enabled pathologists and oncologists to make highly accurate
tissue-of-origin diagnosis in many of these metastatic patients.3,4
However, the current success rate of the diagnostic work-up, even
after exhaustive clinical and pathologic investigation, varies from
20 to 25%.3,4 Consequently, about 5000 new cancer cases are
annually diagnosed with cancer of unknown primary (CUP) in
Canada.
In the absence of a speciﬁc tumour diagnosis, there has been no
consensus of deﬁned treatment guidelines. Several broad-
spectrum empiric chemotherapeutic regimens (not speciﬁc for
any particular type of cancer) based on combination regimens of
platinum or taxane drugs have generally been used.5,6 However,
patients have a poor prognosis with a median survival of 8-12
months from diagnosis and 1-year survival probabilities ranging
from 15 to 35%.3
The ability to identify a primary tumour site is an important goal
in the clinical management of any patient with metastatic cancer.
When tumour origins are known, patient outcomes including
survival may improve because oncologists have better information
on which to base treatment strategies.7,8 This allows patients to
beneﬁt from the increasing availability of speciﬁc chemotherapy
regimens or therapies designed to target biologic characteristics
of speciﬁc malignancies.7,8 Patients may also ﬁnd value in knowing
where their cancer originated from, independent of effects on
prognosis and treatment.
Prediction of the likely primary tumour site by testing the
biopsy specimen of the metastatic tumour is improving through
the use of gene expression proﬁling techniques.9,10 To date,
several gene expression-based tests have demonstrated the
potential value of this approach in identifying the primary
site.4,11–24 One microarray-based test uses 2000-GEP to identify a
tumour’s primary site using formalin-ﬁxed parafﬁn-embedded
(FFPE) specimens (Tissue of Origin test, Response Genetics, Inc.,
Los Angeles, CA).24 The test compares the RNA proﬁle of a tumour
FFPE specimen to established RNA proﬁles of 15 known tissues.
Test results are presented as 15 similarity scores (SS) which are
interpreted as probabilities, one for each of 15 different tissue
types on the panel. The highest SS indicates the most likely tissue
of origin. A maximum SS of 30 or less indicates indeterminate
results which might occur if the specimen harbors less than 20%
tumor content or if the tumour specimen is not represented by
the 15 tissue types included in the test panel.24 Specimen
requirements include a minimum of 20% tumour content, a
maximum of 20% necrosis and a minimum tumor area of 0.5 mm2.
The 2000-GEP test was validated on 462 independent FFPE
specimens derived from metastatic or poorly differentiated tumor
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specimens of known primary cancers and showed 89.3%
sensitivity in identifying tumour’s primary site.24 Based on this
analysis, the test was approved by the Food and Drug
Administration in 201225 and has been available for clinical use
in the United states. The 2000-GEP test results are intended for use
in the context of the patient’s clinicopathologic and radiologic
history by a qualiﬁed oncologist and pathologist.26–28 For instance,
initial or additional clinical history, IHC analyses, and computed
tomography (CT) scan images should be correlated and consistent
with 2000-GEP tumour classiﬁcation when suggesting a potential
primary tumour site.
Although the test has been validated as a diagnostic tool, its
impact on health and economic outcomes, if introduced into
general practice for CUP patients, has not been determined. The
2000-GEP test has an ofﬁcial list price of $4400 CAD per patient.29
As of September 2015, the test is not publically funded in any
Canadian province. Current clinical management of CUP patients
who are left without a primary tumour site diagnosis following
clinical and pathological diagnostic workup undertaken according
to current Canadian clinical practice has not been inﬂuenced by
the availability of 2000-GEP testing. Generation of recommenda-
tions for Canadian clinical practice regarding the use of 2000-GEP
test in CUP requires a comprehensive health economic evaluation
of this approach in the Canadian setting.30 In this project, we
evaluated the incremental cost-effectiveness of using the 2000
GEP test to help identify the primary tumour when current clinical
and pathological diagnostic evaluation fails to provide a diagnosis
of primary tumour site for CUP patients.
METHODS
Model overview
We developed a decision analytic model31 (Figure 1) to estimate the
lifetime clinical and economic consequences of different clinical manage-
ment strategies for patients diagnosed with CUP following their clinical
and pathological diagnostic workup undertaken according to current
Canadian clinical practice. The model begins with a decision to use the
2000-GEP test or to continue with current clinical practice (CCP) (Figure 1a).
In the CCP strategy, we assumed that the primary tumour site stays
undiagnosed and CUP patients are treated according to existing clinical
practice (Figure 1b). In the 2000-GEP-based strategy, we classiﬁed patients
according to their occult primary tumour sites (Figure 1c). For each occult
primary tumour site, we assumed that the 2000-GEP test results would
either be determinate (deﬁned as classiﬁcation of the tumour specimen to
one of the 15 tissue types included in the test panel) or indeterminate
(deﬁned as highest SS is 30 or less) (Figure 1c). Determinate 2000-GEP test
results could either be correct or incorrect tumour classiﬁcation (Figure 1c).
We assumed that determinate 2000-GEP test results would be used in the
context of a patient’s clinicopathologic and radiologic assessment (CRA)
history by a qualiﬁed oncologist and pathologist when suggesting a
primary tumour site (e.g., clinical history, immunohistochemistry analysis,
and computer tomography scan images, etc).26,28,32 When determinate
2000-GEP test classiﬁcation (i.e., correct or incorrect) is found to be
consistent with the CRA, we assumed that the test result will be considered
to suggest a diagnosis of primary tumour which may be correct or
incorrect and guide clinical management (Figure 1c). When determinate
2000-GEP test classiﬁcation is found to be inconsistent with CRA, we
assumed that the test result will not be considered and primary tumour
stays undiagnosed (Figure 1c).
In the 2000-GEP-based strategy, other occult primary tumour sites
represent tumour sites that are not covered by the 15 tissue types included
in the test panel. For these occult primary tumour sites, we assumed that
the 2000-GEP test results would either be indeterminate (deﬁned as
highest SS is 30 or less) or determinate but represent incorrect tumour
classiﬁcation (i.e., incorrect classiﬁcation of the tumour specimen to one of
the 15 tissue types included in the test panel).
CUP patients whose primary tumour stays undiagnosed in both
strategies or those who have their primary tumour incorrectly diagnosed
in the 2000-GEP-based strategy entered Markov model ’A‘ (Figure 1d). CUP
patients whose primary tumour is correctly diagnosed in the 2000-GEP-
based strategy entered Markov model ’B‘ (Figure 1e). Model ’A‘ differs from
model ’B‘ in that it has an additional health state to account for the
possibility that some CUP patients whose primary tumour site is
undiagnosed or incorrectly diagnosed may have their true primary tumor
site (i.e., diagnosis of latent primary tumour site) subsequently identiﬁed
during the course of disease.33
Model ’A‘ simulated monthly transitions among the following ﬁve
distinct health states: (1) Initial diagnosis of metastasis of unknown primary
(IDMUP); (2) diagnosis of latent primary (LP); (3) diagnosis of second
primary (i.e., deﬁned as a new primary malignancy) (SP); (4) palliative care
(PC); and (5) death. Model ’B‘ simulated monthly transitions among the
following four distinct health states: (1) Initial diagnosis of metastasis of
known primary (IDMKP); (2) SP; (3) PC; and (4) death.
The analysis was conducted from the Canadian health care payer’s
perspective. We applied a discount rate of 5% per annum to costs, life
years (LY) and quality adjusted life years (QALYs) following Canadian
guidelines.34 We used a lifetime horizon and half cycle correction.35 We
used TreeAge Software (Tree-Age Software, Inc., Williamstown, MA, USA) to
produce and evaluate the decision analytic model. Data collection and
analysis involving Manitoba administrative databases were approved by
the University of Manitoba Health Research Ethics Board, Manitoba Health
Information Privacy Committee and University of Western Ontario Health
Research Ethics Board.
Identiﬁcation of the study cohort
We used the Manitoba Cancer Registry (MCR) to identify a study cohort
consisting of all patients diagnosed initially with metastatic cancer who
underwent clinical and pathological diagnostic workup in Manitoba during
the period from January 1, 2002 to December 31, 2011. A minimum of two-
year follow-up information from the time of initial diagnosis was available
for each patient. We linked all patients with administrative data held by
Manitoba Health including the Hospital Discharge Database, the Physician
Claims Database and the Drug Program Information Network. We also used
the MCR to identify patients in our study cohort who had a latent primary
(LP) tumour site subsequently detected after their initial diagnosis with
metastatic cancer during their life or through autopsy. Full details are given
in Supplementary Appendix section A.
Distributions and transition probabilities
For each occult primary tumour site in the 2000-GEP model, we extracted
the distribution of patients across 2000-GEP test results (i.e., determinate
versus indeterminate 2000-GEP test results and correct versus incorrect
2000-GEP test classiﬁcation) and across diagnostic results (i.e., correct
diagnosis of primary tumour, incorrect diagnosis of primary tumour, and
undiagnosed primary tumour) from a recent validation analysis24 and
clinical veriﬁcation of the test performance26 (Table 1). We estimated all
other distributions in the decision tree and transition probabilities in the
Markov models (Table 1) from the observed clinical management and
survival outcomes in our study cohort. Full details are given in the
Supplementary Appendix section B and Table A1.
Costs and utilities
The cost of 2000-GEP test is estimated at $4400 CAD per patient.29 We
used the costs of hospital stays, medical claims and prescription claims to
estimate the cost per unit time in each Markov state (Table 2). We derived
utility estimates from secondary sources (Table 3). Full details are given in
the Supplementary Appendix section C and D.
Sensitivity analyses
In deterministic sensitivity analysis we focused on three groups of
parameters: (1) Parameters related to the accuracy of 2000-GEP testing
(akin sensitivity of the test) across occult primary sites (i.e., deﬁned as the
probability of correct 2000-GEP test classiﬁcation given that the test
result is determinate); (2) Parameters related to incorrect diagnostic results
following determinate 2000-GEP test results (i.e., when the primary tumour
stays undiagnosed following correct 2000-GEP test classiﬁcation or when
the primary tumour is incorrectly diagnosed following incorrect 2000-GEP
test classiﬁcation); and (3) Parameters related to survival following correct
primary tumour diagnosis (i.e., the transition probabilities from IDM to PC,
SP, or dead states in the 2000-GEP Markov models following the
chance nodes when the primary is correctly diagnosed). We included
the latter group of parameters in our sensitivity analyses to test the
possibility that CUP patients may not respond as well as their counterparts
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Patients entering Markov model “A” start the model and remain in the IDM state unless they develop LP or SP, start PC, or die. Patients who
developed LP remain in the LP state or transition to SP, PC, or Dead states. Patients entering Markov model “B” start the model and remain in the
IDM state unless they develop SP, start PC, or die. In both Markov models, patients who developed SP, remain in the SP state or make transition to
PC or Dead states. Patients who started PC remain in the PC state or transition to Dead state.
* A decision analytic models are mathematical model used to combine data from several clinical trials or administrative databases as well as expert
clinical and scientific opinion in order to project the impact of medical interventions and estimate their incremental cost-effectiveness ratios (see
Inadomi 31 for an introduction). A decision tree is a common type of decision analytic model and used to simulate a sequence of decisions and
uncertain events that may occur in a simple notion of time (i.e., one direction left to right chronologically). There are no shortcuts in a standard tree
structure for representing events that recur over time (see Inadomi 31 for introduction).
† In the 2,000-GEP-based strategy, other occult primary tumour sites represent tumour sites that are not covered by the 15 tissue types included in
the test panel. For these occult primary tumour sites, we assumed that the 2,000-GEP test results would either be indeterminate (defined as highest
SS is 30 or less) or determinate but represent incorrect tumour classification (i.e., incorrect classification of the tumour specimen to one of the 15
tissue types included in the test panel) 26.
‡ A Markov model is a common type of decision analytic model and used to project scenarios that involve transitions between various states of
health over a short or long period of time. The model allows movement back and forth between health states to represent events that recur over
time (see Sonnenberg and Beck 35 for an introduction).
Abbreviations: CCP = Canadian clinical practice; GEP = Gene expression profiling; CRA = clinicopathologic and radiologic assessment; IDM =
initial diagnosis of metastasis; LP = diagnosis of latent primary; SP = diagnosis of second primary; PC = palliative care.
2,000-GEP test versus CCP-guided clinical management.
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Figure 1. Decision analytic model for CUP*.
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Table 1. Base case probabilities and sources
Variables Base case
value
Range tested in
sensitivity analyses
Distribution used in
PSAa
Data Source
Probability distribution of occult primary tumour sites among CUP
patients (%)
MCR
Bladder 0
Breast 2.4 Dirichlet
Colorectal 13 Dirichlet
Gastric 1.1 Dirichlet
Testicular germ cell 1.1 Dirichlet
Kidney 3 Dirichlet
Hepatocellular 0.6 Dirichlet
Non-small cell lung 14.2 Dirichlet
Non-Hodgkin’s lymphoma 10 Dirichlet
Melanoma 6.5 Dirichlet
Ovarian 13.6 Dirichlet
Pancreas 7.1 Dirichlet
Prostate 3 Dirichlet
Sarcoma 2 Dirichlet
Thyroid 2 Dirichlet
All other tumor sites not covered by the 2000-GEP test panelb 20.4 Dirichlet
Distribution of these tumour sites
Buccal cavity and pharynx 17.8
Esophagus 1.2
Small intestine 3.6
Gallbladder 5.9
Non-hepatocellular 3.6
Other digestive system 14.3
Other female genital system 4.8
Other male genital system 1.2
Small cell lung 8.3
Other lung 26.2
Ureter 2.4
Other urinary system 1.2
Multiple myeloma 8.3
Other endocrine 1.2
Probability of determinate 2000-GEP test result for each tumour site
included in the 2000-GEP test panelb (%)
93 90–100 26
Probability of indeterminate 2000-GEP test results for each tumour site
included in the 2000-GEP test panelc (%)
7 0–10 Beta 26
Probability of determinate 2000-GEP test result for other tumor sites
not covered by the 2000-GEP test panelb (%)
67 26
Probability of indeterminate 2000-GEP test result for other tumor sites
not covered by the 2000-GEP test panelc (%)
33 30–40 Beta 26
Accuracy of 2000-GEP test by occult primary tumour site (%) given a determinate test result
Bladder
Correct classiﬁcation 79.3 60.3–92 24
Incorrect classiﬁcation 20.7 8–39.7 Beta 24
Breast
Correct classiﬁcation 96.5 87.9–99.6 24
Incorrect classiﬁcation 3.5 0.4–12.1 Beta 24
Colorectal
Correct classiﬁcation 91.7 77.5–98.2 24
Incorrect classiﬁcation 8.3 1.8–22.5 Beta 24
Gastric
Correct classiﬁcation 72 50.6–87.9 24
Incorrect classiﬁcation 28 12.1–49.4 Beta 24
Hepatocellular
Correct classiﬁcation 96 79.6–99.9 24
Incorrect classiﬁcation 4 0.1–20.4 Beta 24
Germ cell
Correct classiﬁcation 84 63.9–95.5 24
Incorrect classiﬁcation 16 4.5–36.1 Beta 24
Kidney
Correct classiﬁcation 89.3 71.8–97.7 24
Incorrect classiﬁcation 10.7 0.3–28.2 Beta 24
Melanoma
Correct classiﬁcation 84 63.9–95.5 24
Incorrect classiﬁcation 16 0.5–36.1 Beta 24
Non-Hodgkin’s lymphoma
Correct classiﬁcation 89.7 72.6–97.8 24
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with metastatic of known primary cancers when their occult primary is
identiﬁed and treated with current site-speciﬁc therapy.56 We have
separately performed additional deterministic sensitivity analyses on the
cost of the test and probability of indeterminate test results across occult
primary sites.
We conducted probabilistic sensitivity analysis using Monte Carlo
simulation with 1000 iterations. Each iteration consisted of a random
draw from an appropriate distribution for all model inputs (Tables 1, 2, 3)
to produce a distribution of model outputs.
We also performed a value-of-information analysis57 in which we
estimated the expected monetary value of removing all statistical
uncertainty about the clinical impact of the 2000-GEP test.57,58 In particular,
we compared results with and without uncertainty related to accuracy of
the 2000-GEP test, diagnostic results following determinate 2000-GEP test
results, and survival following correct primary tumour diagnosis.
RESULTS
Base-case scenario
There were 1,080 metastatic patients diagnosed with CUP
who were left without a primary tumour site diagnosis following
clinical and pathological diagnostic workup undertaken
according to clinical practice in Manitoba from January 1, 2002
to December 31, 2011. Patient, tumour, and treatment character-
istics of all the CUP patients are given in the Supplementary
Appendix Table A2. Of those, 169 (15%) patients had their latent
primary tumour site eventually detected during their life. During
the same time period, there were 10 012 patients initially
diagnosed with metastatic cancer of known primary. Of those,
202 (2%) patients had their cancer initially classiﬁed differently
from their latent primary tumour identiﬁed later during life or at
autopsy.
Our model predicted 1.13 LY, 0.63 QALY and $17,802 CAD for
CUP (i.e., CCP-based strategy). By contrast, when the primary
tumour is properly identiﬁed model outcomes ranged from 0.74
LY, 0.45 QALY, and $14,278 for metastatic cancer of hepatocellular
primary tumour to 4.35 LY, 3.37 QALY, and $69,400 CAD for
metastatic cancer of testicular germ cell primary tumour (Table 4).
Overall, the model predicted 1.42 LY, 0.87 QALY and 28,609 CAD
for the 2000-GEP-based strategy.
Table 1. (Continued )
Variables Base case
value
Range tested in
sensitivity analyses
Distribution used in
PSAa
Data Source
Incorrect classiﬁcation 10.3 2.2–27.4 Beta 24
Non-small cell lung
Correct classiﬁcation 85.2 66.3–95.8 24
Incorrect classiﬁcation 14.8 4.2–33.7 Beta 24
Ovarian
Correct classiﬁcation 88.9 75.9–96.3 24
Incorrect classiﬁcation 11.1 3.7–24.1 Beta 24
Pancreas
Correct classiﬁcation 85.7 67.3–96 24
Incorrect classiﬁcation 14.3 4–32.7 Beta 24
Prostate
Correct classiﬁcation 96 79.6–99.9 24
Incorrect classiﬁcation 4 0.1–20.4 Beta 24
Sarcoma
Correct classiﬁcation 88.9 70.8–97.6 24
Incorrect classiﬁcation 11.1 2.4–29.2 Beta 24
Thyroid
Correct classiﬁcation 90.3 74.2–98 24
Incorrect classiﬁcation 9.7 2–25.8 Beta 24
Others
Correct classiﬁcation 0 26
Incorrect classiﬁcation 100 26
Probabilities of diagnostic results following the interpretation of determinate 2000-GEP test results in the context of CRAd (%)
Following correct 2000-GEP test classiﬁcation
2000-GEP test classiﬁcation is consistent with CRA and correct
diagnosis of primary tumour is made
100 0 –100 Beta 26,28,32
2000-GEP test classiﬁcation is inconsistent with CRA and primary
tumour stays undiagnosed
0 0 –100 26,28,32
Following Incorrect 2000-GEP test classiﬁcation
2000-GEP test classiﬁcation is inconsistent with CRA and primary
tumour stays undiagnosed
100 0–100 Beta 26,28,32
2000-GEP test classiﬁcation is consistent with CRA and incorrect
diagnosis of primary tumour is made
0 0–100 26,28,32
Abbreviations: CRA, Clinicopathologic and radiologic assessment; CUP, Cancer of unknown primary; MCR, Manitoba Cancer Registry; PSA, probabilistic
sensitivity analysis; SS, Similarity score. aThe Dirichlet distribution is a multinomial extension of the beta distribution. The Dirichlet distribution was used in PSA
for the probability estimates of occult primary tumour sites to provide probabilistic probabilities over multiple branches (i.e., represent occult primary tumour
sites) that appropriately represent uncertainty while satisfying the requirement that mutually exclusive event probabilities should sum to 1.36 Base-case
probability estimates of 100% were assumed to be 99% in PSA. bThe 2000-GEP test panel covers the following 15 tissue types: Hepatocellular, kidney, non-
small cell lung, ovarian, pancreatic, prostate, and thyroid, melanoma, testicular germ cell, non-Hodgkins lymphoma, and sarcoma. cThe 2000-GEP test result is
classiﬁed as indeterminate when the highest SS is 30 or less due to unique specimens harboring less than 20% tumor content, or actual tissue of origin for a
given tumour specimen is not covered by the 15 tissue types included in the test panel. dDeterminate 2000-GEP test result (i.e., correct or incorrect 2000-GEP
test classiﬁcation) is assumed to be used in the context of the patient’s clinicopathologic and radiologic history by a qualiﬁed oncologist and pathologist. For
example, other available information such as clinical history, immunohistochemistry analysis, and computer tomography scan images are considered when
suggesting a primary tumour site as by 2000-GEP test classiﬁcation. When determinate 2000-GEP test classiﬁcation is found to be inconsistent with CRA, the
test result is not considered and primary tumour stays undiagnosed.
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Table 2. Base case cost estimates and sources
Variables Base case value Duration Distribution used in PSAa Data Source
Cost associated with IDM (per month), $
Breast
First year after IDM
Costs of inpatients and one day procedure stays 983 12 months Log-logistic HA
Physicians and other health care providers cost 257 12 months Log-logistic PC
Cost of prescription claims 73 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 490 Lifetime Log-logistic HA
Physicians and other health care providers cost 131 Lifetime Log-logistic PC
Cost of prescription claims 89 Lifetime Log-logistic DPIN
Colorectal
First year after IDM
Costs of inpatients and one day procedure stays 1273 12 months Log-logistic HA
Physicians and other health care providers cost 533 12 months Log-logistic PC
Cost of prescription claims 73 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 730 Lifetime Log-logistic HA
Physicians and other health care providers cost 284 Lifetime Log-logistic PC
Cost of prescription claims 89 Lifetime Log-logistic DPIN
Gastric
First year after IDM
Costs of inpatients and one day procedure stays 1425 12 months Log-logistic HA
Physicians and other health care providers cost 398 12 months Log-logistic PC
Cost of prescription claims 46 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 1372 Lifetime Log-logistic HA
Physicians and other health care providers cost 271 Lifetime Log-logistic PC
Cost of prescription claims 72 Lifetime Log-logistic DPIN
Hepatocellular
First year after IDM
Costs of inpatients and one day procedure stays 943 12 months Log-logistic HA
Physicians and other health care providers cost 185 12 months Log-logistic PC
Cost of prescription claims 42 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 737 Lifetime Log-logistic HA
Physicians and other health care providers cost 19 Lifetime Log-logistic PC
Cost of prescription claims 27 Lifetime Log-logistic DPIN
Kidney
First year after IDM
Costs of inpatients and one day procedure stays 1353 12 months Log-logistic HA
Physicians and other health care providers cost 373 12 months Log-logistic PC
Cost of prescription claims 78 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 1019 Lifetime Log-logistic HA
Physicians and other health care providers cost 224 Lifetime Log-logistic PC
Cost of prescription claims 93 Lifetime Log-logistic DPIN
Melanoma
First year after IDM
Costs of inpatients and one day procedure stays 508 12 months Log-logistic HA
Physicians and other health care providers cost 290 12 months Log-logistic PC
Cost of prescription claims 78 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 748 Lifetime Log-logistic HA
Physicians and other health care providers cost 164 Lifetime Log-logistic PC
Cost of prescription claims 85 Lifetime Log-logistic DPIN
Non-Hodgkin’s lymphoma
First year after IDM
Costs of inpatients and one day procedure stays 1620 12 months Log-logistic HA
Physicians and other health care providers cost 346 12 months Log-logistic PC
Cost of prescription claims 123 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 1414 Lifetime Log-logistic HA
Physicians and other health care providers cost 183 Lifetime Log-logistic PC
Cost of prescription claims 77 Lifetime Log-logistic DPIN
Non-small lung
First year after IDM
Costs of inpatients and one day procedure stays 885 12 months Log-logistic HA
Physicians and other health care providers cost 241 12 months Log-logistic PC
Cost of prescription claims 33 12 months Log-logistic DPIN
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Table 2. (Continued )
Variables Base case value Duration Distribution used in PSAa Data Source
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 773 Lifetime Log-logistic HA
Physicians and other health care providers cost 164 Lifetime Log-logistic PC
Cost of prescription claims 83 Lifetime Log-logistic DPIN
Ovarian
First year after IDM
Costs of inpatients and one day procedure stays 2618 12 months Log-logistic HA
Physicians and other health care providers cost 392 12 months Log-logistic PC
Cost of prescription claims 69 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 1144 Lifetime Log-logistic HA
Physicians and other health care providers cost 187 Lifetime Log-logistic PC
Cost of prescription claims 58 Lifetime Log-logistic DPIN
Pancreas
First year after IDM
Costs of inpatients and one day procedure stays 1164 12 months Log-logistic HA
Physicians and other health care providers cost 294 12 months Log-logistic PC
Cost of prescription claims 36 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 1345 Lifetime Log-logistic HA
Physicians and other health care providers cost 241 Lifetime Log-logistic PC
Cost of prescription claims 171 Lifetime Log-logistic DPIN
Prostate
First year after IDM
Costs of inpatients and one day procedure stays 961 12 months Log-logistic HA
Physicians and other health care providers cost 243 12 months Log-logistic PC
Cost of prescription claims 60 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 771 Lifetime Log-logistic HA
Physicians and other health care providers cost 119 Lifetime Log-logistic PC
Cost of prescription claims 64 Lifetime Log-logistic DPIN
Sarcoma
First year after IDM
Costs of inpatients and one day procedure stays 1451 12 months Log-logistic HA
Physicians and other health care providers cost 552 12 months Log-logistic PC
Cost of prescription claims 127 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 470 Lifetime Log-logistic HA
Physicians and other health care providers cost 119 Lifetime Log-logistic PC
Cost of prescription claims 176 Lifetime Log-logistic DPIN
Germ cell
First year after IDM
Costs of inpatients and one day procedure stays 1109 12 months Log-logistic HA
Physicians and other health care providers cost 606 12 months Log-logistic PC
Cost of prescription claims 129 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 903 Lifetime Log-logistic HA
Physicians and other health care providers cost 139 Lifetime Log-logistic PC
Cost of prescription claims 26 Lifetime Log-logistic DPIN
Thyroid
First year after IDM
Costs of inpatients and one day procedure stays 854 12 months Log-logistic HA
Physicians and other health care providers cost 417 12 months Log-logistic PC
Cost of prescription claims 39 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 484 Lifetime Log-logistic HA
Physicians and other health care providers cost 89 Lifetime Log-logistic PC
Cost of prescription claims 45 Lifetime Log-logistic DPIN
CUP
First year after IDM
Costs of inpatients and one day procedure stays 1145 12 months Log-logistic HA
Physicians and other health care providers cost 210 12 months Log-logistic PC
Cost of prescription claims 51 12 months Log-logistic DPIN
After ﬁrst year of IDM
Costs of inpatients and one day procedure stays 541 Lifetime Log-logistic HA
Physicians and other health care providers cost 90 Lifetime Log-logistic PC
Cost of prescription claims 100 Lifetime Log-logistic DPIN
Cost associated with latent primary (per month), $
Patients initially diagnosed with CUP
First year after latent primary
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Table 2. (Continued )
Variables Base case value Duration Distribution used in PSAa Data Source
Costs of inpatients and one day procedure stays 970 12 months Log-logistic HA
Physicians and other health care providers cost 191 12 months Log-logistic PC
Cost of prescription claims 88 12 months Log-logistic DPIN
After ﬁrst year of latent primary
Costs of inpatients and one day procedure stays 1724 Lifetime Log-logistic HA
Physicians and other health care providers cost 150 Lifetime Log-logistic PC
Cost of prescription claims 88 Lifetime Log-logistic DPIN
Cost associated with palliative care (per month), $
Breast
Costs of inpatients and one day procedure stays 1214 Lifetime Log-logistic HA
Physicians and other health care providers cost 236 Lifetime Log-logistic PC
Cost of prescription claims 98 Lifetime Log-logistic DPIN
Colorectal
Costs of inpatients and one day procedure stays 1226 Lifetime Log-logistic HA
Physicians and other health care providers cost 204 Lifetime Log-logistic PC
Cost of prescription claims 77 Lifetime Log-logistic DPIN
Gastric
Costs of inpatients and one day procedure stays 790 Lifetime Log-logistic HA
Physicians and other health care providers cost 149 Lifetime Log-logistic PC
Cost of prescription claims 56 Lifetime Log-logistic DPIN
Germ cell
Costs of inpatients and one day procedure stays 594 Lifetime Log-logistic HA
Physicians and other health care providers cost 10 Lifetime Log-logistic PC
Cost of prescription claims 0 Lifetime Log-logistic DPIN
Kidney
Costs of inpatients and one day procedure stays 1277 Lifetime Log-logistic HA
Physicians and other health care providers cost 259 Lifetime Log-logistic PC
Cost of prescription claims 184 Lifetime Log-logistic DPIN
Hepatocellular
Costs of inpatients and one day procedure stays 544 Lifetime Log-logistic HA
Physicians and other health care providers cost 142 Lifetime Log-logistic PC
Cost of prescription claims 27 Lifetime Log-logistic DPIN
Non-small lung
Costs of inpatients and one day procedure stays 1116 Lifetime Log-logistic HA
Physicians and other health care providers cost 175 Lifetime Log-logistic PC
Cost of prescription claims 67 Lifetime Log-logistic DPIN
Non-Hodgkin’s lymphoma
Costs of inpatients and one day procedure stays 1012 Lifetime Log-logistic HA
Physicians and other health care providers cost 242 Lifetime Log-logistic PC
Cost of prescription claims 268 Lifetime Log-logistic DPIN
Melanoma
Costs of inpatients and one day procedure stays 853 Lifetime Log-logistic HA
Physicians and other health care providers cost 241 Lifetime Log-logistic PC
Cost of prescription claims 94 Lifetime Log-logistic DPIN
Ovarian
Costs of inpatients and one day procedure stays 1182 Lifetime Log-logistic HA
Physicians and other health care providers cost 158 Lifetime Log-logistic PC
Cost of prescription claims 71 Lifetime Log-logistic DPIN
Pancreas
Costs of inpatients and one day procedure stays 819 Lifetime Log-logistic HA
Physicians and other health care providers cost 144 Lifetime Log-logistic PC
Cost of prescription claims 55 Lifetime Log-logistic DPIN
Prostate
Costs of inpatients and one day procedure stays 1358 Lifetime Log-logistic HA
Physicians and other health care providers cost 200 Lifetime Log-logistic PC
Cost of prescription claims 88 Lifetime Log-logistic DPIN
Sarcoma
Costs of inpatients and one day procedure stays 1215 Lifetime Log-logistic HA
Physicians and other health care providers cost 197 Lifetime Log-logistic PC
Cost of prescription claims 112 Lifetime Log-logistic DPIN
Thyroid
Costs of inpatients and one day procedure stays 463 Lifetime Log-logistic HA
Physicians and other health care providers cost 102 Lifetime Log-logistic PC
Cost of prescription claims 49 Lifetime Log-logistic DPIN
CUP
Costs of inpatients and one day procedure stays 1233 Lifetime Log-logistic HA
Physicians and other health care providers cost 184 Lifetime Log-logistic PC
Cost of prescription claims 83 Lifetime Log-logistic DPIN
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Compared to CCP, the 2000-GEP-based strategy led to an
increase of 0.28 LY and 0.24 QALY per person and an increase in
cost of $10,807 CAD per person of which $4,400 is the cost of the
test itself, resulting in an incremental cost effectiveness ratio (ICER)
of $37,774 per LY gained and $44,151 per QALY. The clinical
beneﬁt of 0.28 LY is comparable to recently reported data
showing an improved survival of 3.4 months for CUP patients
received site-speciﬁc therapy based on a GEP diagnosis when
compared to historical control patients.8
Budget impact analysis
We estimated the total expense of incorporating the 2000-GEP test
into standard practice in Canada for CUP patients when current
Table 2. (Continued )
Variables Base case value Duration Distribution used in PSAa Data Source
Cost associated with second primaryb(per month), $
Breast
Costs of inpatients and one day procedure stays 527 Lifetime Log-logistic HA
Physicians and other health care providers cost 265 Lifetime Log-logistic PC
Cost of prescription claims 42 Lifetime Log-logistic DPIN
Colerectal
Costs of inpatients and one day procedure stays 1283 Lifetime Log-logistic HA
Physicians and other health care providers cost 511 Lifetime Log-logistic PC
Cost of prescription claims 128 Lifetime Log-logistic DPIN
Gastric
Costs of inpatients and one day procedure stays 464 Lifetime Log-logistic HA
Physicians and other health care providers cost 102 Lifetime Log-logistic PC
Cost of prescription claims 11 Lifetime Log-logistic DPIN
Germ cell
Costs of inpatients and one day procedure stays 711 Lifetime Log-logistic HA
Physicians and other health care providers cost 1217 Lifetime Log-logistic PC
Cost of prescription claims 27 Lifetime Log-logistic DPIN
Kidney
Costs of inpatients and one day procedure stays 2518 Lifetime Log-logistic HA
Physicians and other health care providers cost 285 Lifetime Log-logistic PC
Cost of prescription claims 164 Lifetime Log-logistic DPIN
Non-small lung
Costs of inpatients and one day procedure stays 1147 Lifetime Log-logistic HA
Physicians and other health care providers cost 317 Lifetime Log-logistic PC
Cost of prescription claims 62 Lifetime Log-logistic DPIN
Non-Hodgkin’s lymphoma
Costs of inpatients and one day procedure stays 876 Lifetime Log-logistic HA
Physicians and other health care providers cost 343 Lifetime Log-logistic PC
Cost of prescription claims 138 Lifetime Log-logistic DPIN
Melanoma
Costs of inpatients and one day procedure stays 1022 Lifetime Log-logistic HA
Physicians and other health care providers cost 437 Lifetime Log-logistic PC
Cost of prescription claims 166 Lifetime Log-logistic DPIN
Ovarian
Costs of inpatients and one day procedure stays 600 Lifetime Log-logistic HA
Physicians and other health care providers cost 202 Lifetime Log-logistic PC
Cost of prescription claims 29 Lifetime Log-logistic DPIN
Prostate
Costs of inpatients and one day procedure stays 1573 Lifetime Log-logistic HA
Physicians and other health care providers cost 254 Lifetime Log-logistic PC
Cost of prescription claims 83 Lifetime Log-logistic DPIN
Sarcoma
Costs of inpatients and one day procedure stays 1246 Lifetime Log-logistic HA
Physicians and other health care providers cost 517 Lifetime Log-logistic PC
Cost of prescription claims 256 Lifetime Log-logistic DPIN
Thyroid
Costs of inpatients and one day procedure stays 219 Lifetime Log-logistic HA
Physicians and other health care providers cost 142 Lifetime Log-logistic PC
Cost of prescription claims 48 Lifetime Log-logistic DPIN
CUP
Costs of inpatients and one day procedure stays 910 Lifetime Log-logistic HA
Physicians and other health care providers cost 307 Lifetime Log-logistic PC
Cost of prescription claims 34 Lifetime Log-logistic DPIN
Abbreviations: CUP, Cancer of unknown primary ; DPIN, Drug Program Information Network records; IDM, Initial diagnosis of metastasis; HA, Hospital abstracts;
MCR, Manitoba Cancer Registry; PC, physician claims; PSA, probabilistic sensitivity analysis. aNormal distributions were used for cost parameters in the PSA to
simulate uncertainty at the population level. bPatients initially diagnosed with metastatic hepatocellular and pancreatic cancer did not have a second primary
over the study follow up period and thus costs associated with second primary are not included for hepatocellular and pancreas. Full details on estimation
procedures found in Supplementary Appendix section C.
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diagnostic evaluation fails to provide a diagnosis of primary tumour.
In Manitoba, there were 120 patients diagnosed with CUP in 2010.
Based on the population of Manitoba relative to the rest of Canada
(1.2 million versus 33.5 million at the 2011 census), we anticipate
approximately 3350 patients diagnosed with CUP annually could be
eligible for the 2000-GEP test in Canada. The resulting total annual
budget impact was $36.2 million CAD per year of which $14.7 million
was due to 2000-GEP testing alone and $21.5 million was due to
changes in the management of CUP following 2000-GEP testing.
Sensitivity analysis
The 2000-GEP-based strategy generated an ICER greater than
$100,000 per QALY gained when the accuracy of the 2000-GEP
test decreased by 50%, incorrect diagnostic results following 2000-
GEP test classiﬁcation increased by 20% and survival following
correct primary diagnosis decreased by 30% (Figure 2). In separate
analyses, the cost of the test and probability of indeterminate test
results across occult primary sites did not substantially inﬂuence
our baseline outcomes.
Table 3. Utility values and sources
Health states Utilitya Duration Range tested in
sensitivity analyses
Distribution used
in PSA
Data
Sourceb
Initial diagnosis of metastasis of known primary
Breast 0.715 LT -20% – +20% Beta 38
Colorectal 0.730 LT -20% – +20% Beta 39
Gastric 0.729 LT -20% – +20% Beta 40
Hepatocellular 0.650 LT -20% – +20% Beta 41
Kidney 0.760 LT -20% – +20% Beta 42
Melanoma 0.580 LT -20% – +20% Beta 43
Non-Hodgkin’s lymphoma 0.805 LT -20% – +20% Beta 44
Non-small Lung 0.530 LT -20% – +20% Beta 45
Ovarian 0.740 LT -20% – +20% Beta 46
Pancreas 0.600 LT -20% – +20% Beta 47
Prostate 0.740 LT -20% – +20% Beta 48
Sarcoma 0.690 LT -20% – +20% Beta 49
Testicular germ cell 0.776 LT -20% – +20% Beta 50,51
Thyroid 0.780 LT -20% – +20% Beta 51,52
Other primary tumour sites
Buccal cavity and pharynx 0.670 53
Esophagus 0.670 53
Small intestine 0.730 39
Gallbladder 0.650 41
Non-hepatocellular 0.650 41
Other digestive system 0.730 39
Other female genital system 0.740 46
Other male genital system 0.740 48
Small cell lung 0.530 45
Other lung 0.530 45
Ureter 0.760 42
Other urinary system 0.760 42
Multiple myeloma 0.805 44
Other endocrine 0.800 51,52
Weighted average utility of other
primary tumour sitesc
0.649 LT -20% – +20% Beta
Weighted average utility of metastasis
of known primaryc
0.645
Initial diagnosis of metastasis of unknown
primary d
0.560 LT -20% – +20% Beta 37
Diagnosis of latent primary tumour Utility of metastasis of the corresponding
primary tumoure
LT -20% – +20% Beta
Diagnosis of Second primary tumour 7% reduction in the utility of the previous
health statef
LT -20% – +20% Beta 54
Palliative care 0.4 LT -20% – +20% Beta 55
Death 0
Abbreviations: CUP, cancer of unknown primary; LT, lifetime; PSA, Probabilistic sensitivity analysis. aAll utility estimates were based on EuroQOL ﬁve dimensions
questionnaire (EQ-5D). bWhen EQ-5D estimates are not available the European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire Core 30 (EORTC QLQ-C30) utility estimates were converted to EQ-5D estimates according to mapping model described by Kim et al.51
cWeighted average was based on the observed distribution of latent primary tumour sites in our CUP cohort (Table 1). dUtility with CUP was derived after
applying 13% reduction on the weighted average utility of metastasis of known primary. eFor example, if a latent primary tumour is detected in the course of
metastatic disease for a CUP patient and found to be breast tumour, then this patient will transition to the ’diagnosis of latent primary tumour‘ state and
receive the utility of metastasis of breast cancer (which is equal to 0.715) while remaining in this health state unless this patient transition to other health
states. fFor example, when a second primary tumour is detected in the course of metastatic disease of a CUP patient following Markov model ’A‘, this patient
will transition from the ’initial diagnosis of metastasis of unknown primary‘ state (i.e., utility = 0.56) to the ’diagnosis of second primary tumour‘ state and
receive 7% reduction in the utility of metastasis of unknown primary (i.e., 0.56 – (0.56*0.07) = 0.52) while remaining in this health state, unless this patient
transitions to other health states. Full details on estimation procedures found in Supplementary Appendix Section D.
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Using willingness to pay thresholds of $50,000 and $100,000 per
QALY gained in probabilistic sensitivity analysis (Figure 3a), we
found that the 2000-GEP-based strategy was the preferred
strategy in 78.2 and 99.6% of simulations, respectively (Figure 3b).
Using our baseline ICER value of $44,151 per QALY gained as
the willingness to pay, the opportunity cost associated with the
choice of 2000-GEP-based strategy for guiding management of
CUP resulted in a total expected value of partial perfect
information (EVPPI) of $1266 per patient diagnosed with CUP of
which $450 was due to uncertainty related to accuracy of the
2000-GEP test, $320 was due to uncertainty related to diagnostic
results following determinate 2000-GEP test results, and $496 was
due to uncertainty related to accuracy of survival following correct
primary tumour diagnosis. The resulting total EVPPI for the entire
CUP population that could be eligible for the 2000-GEP test in
Canada was 3350 cases of CUP per year × $1266 per patient =
$4.2 million CAD per year.
DISCUSSION
We developed a decision-analytic model to evaluate the cost
effectiveness of using the 2000-GEP test to help identify primary
tumours when current clinical and pathological diagnostic
evaluation fails to provide a diagnosis of primary tumour site in
CUP patients. In the base case, we estimated that the 2000-GEP-
based strategy has an ICER of $37,774 per LY gained and $44,151
per QALY gained. These ICERs are below ICER estimates for a
21-GEP assay59,60 and cancer drugs that were recently recom-
mended for adoption.61,62 The clinical beneﬁt of 0.28 LY is
comparable to several recently approved drugs for metastatic
disease.63–66 The budget impact analysis shows that adoption of
the 2000-GEP testing would lead to total incremental cost of $36.2
million per year.
Hospital laboratories in Canada receive ﬁxed provincial funding
to support all their operations and it is unlikely at this time that
laboratories would reduce funding of other services to fund GEP
tests conducted exclusively out of country.67 Decisions to adopt
these tests for funding are likely made at the provincial level but
the processes and criteria used by the provincial ministries of
health to evaluate and approve GEP tests are still evolving and yet
to be deﬁned.67 However, the 2000-GEP test characteristics are
comparable to those of the 21-GEP test for guiding adjuvant
chemotherapy in early stage breast cancer which represents the
ﬁrst and only GEP test translated into clinical practice in Canada.
Similar to the 2000-GEP test, the 21-GEP test was found promising
as it may improve patient safety and likely pose low risk of harm,
but had signiﬁcant uncertainty associated with its clinical
value.59,60 Budget impact analyses also demonstrated that
adoption of the 21-GEP testing would lead to a total incremental
cost of up to $23.5 million per year.59,60 The test was recently
funded in several provinces within the context of ﬁeld evaluations.
Given the 2000-GEP test appears to be clinically promising and
provides good value for money34,68 it could also be considered for
special coverage such as coverage with evidence development.57
A recent cost-effectiveness analysis of the 2000-GEP test was
reported among patients with metastatic and poorly differen-
tiated cancer of uncertain primaries (i.e., difﬁcult-to-diagnose
primary) for whom the majority had primary tumour site
diagnoses reported by their physicians prior to 2000-GEP
testing.69 The test was found to have an ICER of $46,858 per
QALY gained from a US third-party payer perspective.69 These
results in uncertain cancers cannot be extrapolated to the CUP
setting because CUP patients are left without a primary tumour site
diagnosis despite extensive clinical and pathological diagnostic
evaluation. As a result management and clinical outcomes of CUP
are different from those of cancer of uncertain primary.
Our sensitivity analyses demonstrated that the 2000-GEP test
accuracy, diagnostic results following 2000-GEP test classiﬁcation
and survival response following correct primary diagnosis are
important variables that inﬂuenced the ICER (Figure 2). For
instance, when these three groups of parameters were negatively
modiﬁed by approximately 35% (Figure 2d) the ICER became well
above ranges of a number of cancer treatments recently approved
for funding in Canada61,62 and the 2000-GEP-based strategy may
no longer deemed a cost effective use of resources. Our value-of-
information analysis demonstrated that there is a signiﬁcant
societal beneﬁt from future research that can better characterize
these three groups of parameters. Taken together with the lack of
future randomized trials of 2000-GEP testing in CUP population
worldwide,70 this suggests that clinical veriﬁcations and ﬁeld
evaluations of the test to establish its impact on Canadian
management of CUP and resulting survival outcomes should be a
priority.
Table 4. Baseline outcomes of Markov models by decision model strategy, Markov model structure and primary tumour site
Strategy Markov model structure Primary tumour site Effectiveness Cost
LY QALY
CCP- and 2000-GEP-based strategya ’A’ Unknown primary 1.13 0.63 $17,802
2000-GEP-based strategyb ’B’ Breast 1.79 1.08 $30,874
Colorectal 2.00 1.40 $38,978
Gastric 1.09 0.73 $26,985
Hepatocellular 0.74 0.45 $14,278
Kidney 1.51 1.02 $34,157
Melanoma 2.30 1.29 $33,056
Non-Hodgkin’s lymphoma 3.05 2.41 $68,662
Non-small Lung 1.08 0.53 $20,165
Ovarian 1.86 1.31 $50,000
Pancreas 0.75 0.43 $18,157
Prostate 2.62 1.78 $40,942
Sarcoma 1.88 1.22 $36,015
Testicular germ cell 4.35 3.37 $69,400
Thyroid 3.77 2.97 $40,200
Abbreviations: LY, life year; QALY, quality adjusted life year. aMarkov model structure ’A‘ was used in the CCP-based strategy and the 2000-GEP-based strategy
when the primary tumour remains undiagnosed or is incorrectly diagnosed. bMarkov models structure ’B‘ were only used in the 2000-GEP-based strategy
when the primary tumour is correctly identiﬁed.
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Validation of any diagnostic test accuracy and clinical
veriﬁcation of resulting diagnostic decisions in a real-life CUP
population remains a challenge since, by deﬁnition, the primary
tumour site is not found except rarely in the clinical course
of disease or more commonly at autopsy.33,71 For instance,
validation analysis of the 2000-GEP test24 used in our study was
conducted in the United States in patients with known primary
cancers. Genetic proﬁles of occult cancers giving rise to CUP may
differ from known primary cancers.71 A more direct study to
evaluate the reliability of any GEP test and its impact on diagnostic
decision making in CUP patients would be the correlation with an
eventual primary tumour detected later during the course of the
disease (latent primary) or at autopsy. This is possible because our
analysis demonstrated that those cases are identiﬁable using
cancer registries and future studies can further link such cases
with their specimens from banks of tumour tissue samples to
study any GEP test. This research approach is warranted to address
concerns over potential incorrect 2000-GEP test classiﬁcation and
resulting diagnostic decisions; it would also be valuable for
updating our model and verifying our results. Future clinical
veriﬁcation and ﬁeld evaluations studies of GEP testing in CUP
population should also explore any potential impact of
Baseline Survival Response Following Correct Primary
Diagnosis 
10% Decrease of Baseline Survival Response Following
Correct Primary Diagnosis 
20% Decrease of Baseline Survival Response Following
Correct Primary Diagnosis 
30% Decrease of Baseline Survival Response Following
Correct Primary Diagnosis 
ICER $50,000per QALY gained
* 2,000-GEP test agreement with reference cancer diagnosis.
† Incorrect diagnostic result was defined as occurring when either the primary stays undiagnosed following correct 2,000-GEP test classification
of the tumour specimen or when the primary tumour is incorrectly diagnosed following incorrect 2,000-GEP test classification of the tumour
specimen.
‡ Survival response following correct primary diagnosis was defined as the transition probabilities from IDM to PC, SP, or dead states in the
2,000-GEP Markov models following the chance nodes when the primary is correctly diagnosed. Survival response following correct diagnosis
of hepatocellular, pancreas or non-small lung primary site was not included in sensitivity analyses as these potential primary sites were found to
have worse QALYs compared to overall CUP group (Table 4).
Abbreviations: 2,000-GEP test = Tissue of Origin test; ICER = incremental cost effectiveness ratio; QALY = quality adjusted life year; CUP =
cancer of unknown primary.
$50,000 < ICER $100,000 per QALY
$100,000 < ICER $150,000 per QALY ICER > $150,000 per QALY
Figure 2. Multivariate sensitivity analysis of the ICER with respect to 2000-GEP accuracy*, incorrect diagnostic results† following 2000-GEP test
classiﬁcation and survival response‡ following correct primary diagnosis.
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intratumour heterogeneity on its results using multiple tumour-
biopsy samples.72
Our analysis has limitations. The estimated distribution of
underlying primary tumours among CUP patients in our study
does not necessarily reﬂect the distribution of underlying primary
tumours among current CUP patients. Potential recent changes in
the incidence of underlying different primary tumours in CUP
population may affect the cost-effectiveness of the 2000-GEP
testing. Outcomes and costs of therapies given in the 2002-2011
population do not also necessarily reﬂect the possible beneﬁts
and costs of newer site-directed therapies or dosing schedules
used in very recent clinical practice so analysis with such data
would be more applicable to the current practice landscape. It is
unclear how the inclusion of these recent therapies may impact
our results because patients with CUP represent a heterogeneous
group and some new therapies might be marginally effective
across certain tumour types.70 Generalization of our study results
to other health care systems may be limited by differences
of clinical practice and different approaches to pricing and
reimbursement.
CONCLUSION
We found that the 2000-GEP test provides good value for money
in CUP patients for whom current clinical and pathological
diagnostic evaluation does not provide a diagnosis of primary
tumour site. However, clinical veriﬁcations and ﬁeld evaluations of
the test using multiple tumour-biopsy samples to establish its
accuracy and impact on diagnostic decisions and survival in the
CUP setting should be initiated in Canada to ensure its clinical
utility.
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